- Home
- Equipment
- usa california
- small molecule targeted drug
Show results for
Refine by
Small Molecule Targeted Drug Equipment Supplied In Usa California
6 equipment items found
Manufactured by:Bexson Biomedical based inSanta Barbara, CALIFORNIA (USA)
Pharmaceutical technology for liquid formulations. A patented 7-Valence Salt revolutionizing small molecule ...
Manufactured by:SomaGenics, Inc. based inSanta Cruz, CALIFORNIA (USA)
RNA interference (RNAi) is a naturally occurring process by which RNA molecules inhibit gene expression either pre- or post-transcriptionally. The discovery of RNAi led to a better understanding of gene regulation and opened the door to exciting new applications in research and therapeutics. The 2006 Nobel price was awarded in recognition of this revolutionary ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-ICI-AC is a niclosamide-based, oral, small molecule anti-inflammatory inhibitor therapy for the treatment of immune checkpoint inhibitor (ICI)-associated colitis and diarrhea in metastatic cancer patients. The PASSPORT clinical trial, a Phase 2a study to determine the safety and potential efficacy of niclosamide in the treatment of ICI-AC, received FDA IND clearance in Q4 ...
Manufactured by:Siolta Therapeutics based inSan Carlos, CALIFORNIA (USA)
Siolta’s Precision Symbiotics Platform enables rapid LBP development. A platform focused on translating microbiome science into novel therapeutics for a healthier world. Siolta’s patient-centric platform leverages our internal expertise in microbiome data analysis, machine learning, anaerobic microbiology, and translational studies to rationally design and optimize multi-strain live ...
Manufactured by:Juvena Therapeutics, inc. based inRedwood City, CALIFORNIA (USA)
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. The characteristics of secreted proteins render them a rich pool of drug candidates for chronic and age-related diseases. Our therapeutic approach is to unlock the potential of these proteins, starting with ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept ...